Pharmacological preconditioning with adenosine A₁ receptor agonist suppresses cellular immune response by an A_2A receptor dependent mechanism

详细信息    查看全文

• 作者：Oshri Naamani^a ; ^{naamanio@post.bgu.ac.il" class="auth_mail} ; Cidio Chaimovitz^b ; Amos Douvdevani^a
• 关键词：A1R ; adenosine A1 receptor ; · ; A2AR ; adenosine A2A receptor ; IPC ; ischemic preconditioning ; PPC ; pharmacological preconditioning ; IR ; ischemia&ndash ; reperfusion ; IRI ; ischemia&ndash ; reperfusion injury ; CCPA ; 2-Chloro-N(6)-cyclopentyladenosine ; ZM241385 ; 4-(2-[7-Amino-2-(2-furyl)[1 ; 2 ; 4]tri­ ; azolo[2 ; 3-a][1 ; 3 ; 5]triazin-5-ylamino]ethyl)phenol
• 刊名：International Immunopharmacology
• 出版年：May 2014
• 年：2014
• 卷：20
• 期：1
• 页码：205-212
• 全文大小：856 K

文摘

Under stressful conditions such as ischemia, sepsis, and severe trauma, adenosine levels are elevated and protect the tissue by interaction with G coupled receptors.

In a model of peritonitis, we previously found that pharmacological preconditioning (PPC) of mice with a selective adenosine A₁ receptor (A₁R) agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA), induced the A_2AR which reduces cytokine secretion and leukocyte recruitment. In our present study we determined whether mice PPC will moderate cellular immune response by the same mechanism. Similar to the effect on inflammation, PPC reduced the response to lymphocyte mitogens and allogeneic MLR response. The inhibitory effect of PPC on the immune response was A₁R and A_2AR dependent as illustrated by experiments with antagonists of these receptors and mice with knock down (KO) receptors. In MLR with PPC splenocytes we found reduced levels of pro-inflammatory cytokines (IFN-纬, IL-15, TNF-伪) and elevation of IL-10, as well as elevation of regulatory T-cell.

Our data indicate that PPC is able to remarkably suppress cellular immune response due to the sensitization A_2AR. This effect of PPC sheds light on the protective role of adenosine in ischemic preconditioning and makes this treatment candidate for the prevention of graft rejection.